NHS to lose on new drugs, pharma firm Novartis warns

NHS patients will lose access to new state -of -the -art treatments due to skyrocketing costs, pharmaceutical giants Novartis claimed a row on a drug pricing deals.

Last week, heath has received a warning after interaction on the cost of drugs for UK between Secretary Wes Streeting and Pharma firms.

A body assesses whether a new drug is a price for money before approved for use on NHS, but Novartis said that its methods were old and made it difficult to approve and launch innovative drugs.

The UK boss Johan Kahlstrom, the UK boss, said the cost means the UK was “called uninterrupted”, but Streeting has vowed that it would not allow firms to “rip” taxpayers.

Swiss firm Novartis stated that it was not considering the UK for major new investments in manufacturing, research or advanced technology due to “systemic obstacles”.

In 2023, a deal was made with the predictions of how big the exemption should be that pharma companies would have to pay the NHS above an agreed limit to the UK government on sale.

A rate of 15% was expected, aimed at preventing the costs of healthcare from spilling out of control.

However, the actual discount rate has increased by 23.5%, which Novartis stated that for example, Germany had more than 7% triple.

The firm, which employs 78,000 people globally, said that the patients were completely losing or missing the new remedies. As a result of the current situation.

It said that due to the “declining competition” of the UK market, the company “was already unable to launch many drugs in the country” for public reimbursement – drugs that are, or soon, will be available to patients in other European countries “.

The company said, “The concern is that future launch and research investment can be more disorganized to the UK if the environment remains unexpected,” the company said.

The UK government said that it has carried forward a liberal and unprecedented proposal to “accelerate development in the drug sector”.

A statement said, “It would have reduced the payment rates for pharmaceutical companies year-on-year, freeing about 1 billion pounds in three years for new, life-changing drugs.”

Streeting earlier told The Guardian that pharmaceutical companies were “short -sighted” in their views for talks.

He told the newspaper: “The pharmaceutical industry signed the deal with the previous government.

“When it was more expensive to the industry than expected, we carried forward an unprecedented proposal to bring the payment rates for all future years of the plan and to speed up the region – but ABPI (Association of the British Pharmaceutical Industry) failed to reach an agreement.”

ABPI Chief Executive Officer Richard Turbate said in a statement that the demand for innovative drugs has been increasing, but the investment in new remedies was falling due to the “company’s revenue” untreated and punitive discounts.

He said that the methods of evaluation of Britain for new drugs were not “changed for approximately a quarter of a century”.

“Without change, the UK will continue to demolish the international league tables for research, investment and drugs,” he said, “he said.

He said that the industry still believes that the line resolve was possible.

The National Institute for Health and Care Excellence (NICE) decides whether a new drug is cost effective. It uses a unit of measurement called “QALY” – “Quality -Samson Life Year”, which will cost you a year of healthy life, detects the effectiveness of the drug in this context.

It considers drugs ranging between £ 20,000 and £ 30,000 per QALY as a good value for money.

However, Norvartis claimed that Nice’s thresholds were old as the cost since 1999 has been the same and not interacted with increasing inflation. It assumes that the current QALY figures are £ 50,000.

Mr. Kahlstrom, Managing Director of UK and Ireland Operations of Novartis, told the BBC’s Today program that the UK “remains an outsider and the patients are still defeated and I think we have to be honest about it”.

He said that the UK was invested on drugs with “NHS only 9% of the healthcare budget”, which was being spent on drugs in France and 15% in Germany.

Mr. Kahlstrom’s comments have come only a few days after the Sunday Times, stating that another pharmaceutical company will not present its breast cancer medicine for evaluation by the company, Gillid Sciences, UK, blames the UK for “underwelling drugs”.